MARKET WIREYahoo Finance • 1d ago
PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowYahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
Why PMVP Stock surged +4.58% Today — RQD Quant Desk Flash
$1.37 +4.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.38
PMV Pharmaceuticals Inc. (PMVP) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $98.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PMVP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PMVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, PMV Pharmaceuticals Inc. (NASDAQ: PMVP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (+4.58% 1D, market cap $98.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PMVP ranks #426 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PMVP compare to ORGO and VTVT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMVP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $99.5M). Among the 5-stock peer group, PMVP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PMVP?
▼
Per PMVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699382), PMV Pharmaceuticals Inc. generated $241.4M in revenue (+0.9% YoY), -$77.7M in net income, and -$73.6M in free cash flow against $116.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.38 (+0.63%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMVP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY PMVP SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (33% of score)
FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 47.5 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.35+3% Next Q
34
Q2 (-2Q)Grade E$1.39-10.1% Next Q
37
Q3 (-1Q)Grade E$1.25+9.6% Next Q
39
CurrentGrade D-$1.37-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PMVP Turnaround Squeeze
While PMVP currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.38) and Max Pain ($1.44) forces dealer call-delta covering toward $2.01.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMVP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PMVP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PMVP Stock surged +4.58% Today — RQD Quant Desk Flash
PMV Pharmaceuticals Inc. (PMVP) surged +4.58% to $1.37, trading at 39% of its 52-week range ($1.02 – $1.91). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 39% of its 52-week range ($1.02 – $1.91) with RSI-14 at 47.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PMVP Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunitySeeking Alpha report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updateskalkine.ca report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
PMV Pharmaceuticals, Inc. Estimates – NASDAQ:PMVPTradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 2d ago
PMV Pharma appoints Matt Eckler to board of directors By Investing.comInvesting.com India report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 2d ago
PMV Pharmaceuticals stock moves above 200-day average as analysts stay mixedad-hoc-news.de report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
Should You Buy PTC Inc. (PTC) After Golden Cross?Yahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
PMVP Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMVP)
- ✓Walkthrough of PMVP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PMVP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.14%▲ ASCENDING CHANNEL
2026-11-03O $1.35H $1.37L $1.31C $1.37VOL 1.21M
RES: $2.10SUP: $1.11SMA50: $1.38SMA200: $1.30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PMVP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PMVP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PMVP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PMVP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMVP)
Health Care Rank #426 of 1015
⚔️ ORGO vs PMVP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PMVP vs. ORGO, VTVT, NRXP, NTHI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, PMV Pharmaceuticals Inc. (PMVP) ranks #426 by composite RQD confidence (42/100, grade D-) and #653 by equity capitalization ($98.9M). Within this direct 5-issuer industry benchmark cohort, PMVP leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. PMVP currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PMVP
ACTIVE
PMV Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +4.58% | $98.9M | Benchmark Subject |
| ORGO Organogenesis Holdings Inc. (Class A) | E | 34/100 | — | — | 17.1% | -1.64% | $98.8M | /orgo-vs-pmvp → |
| VTVT vTv Therapeutics Inc. (Class A) | E | 24/100 | — | — | -35.0% | -4.05% | $99.5M | /vtvt-vs-pmvp → |
| NRXP NRX Pharmaceuticals Inc. | E | 25/100 | — | 58.8% | -35.0% | -4.40% | $98.3M | /nrxp-vs-pmvp → |
| NTHI NeOnc Technologies Holdings Inc. | E | 31/100 | — | — | -35.0% | -5.83% | $97.0M | /nthi-vs-pmvp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001699382 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMV Pharmaceuticals Inc. (PMVP) reported GAAP revenue of $241.4M (+0.9% vs. FY2024 revenue of $239.3M , and +7.6% cumulative change since FY2023) , GAAP net income of -$77.7M, operating cash flow of -$73.6M, and free cash flow of -$73.6M (-41.7% YoY). On the balance sheet, PMVP closed FY2025 with $116.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $241.4M | -$77.7M | -$73.6M | -$73.6M | $116.6M | — |
| FY2024 (FY) | 2024-12-31 | $239.3M | -$58.9M | -$51.3M | -$51.9M | $191.3M | — |
| FY2023 (FY) | 2023-12-31 | $224.4M | -$69.0M | -$55.7M | -$55.7M | — | — |
3. PMVP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PMVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, PMV Pharmaceuticals Inc. (NASDAQ: PMVP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (+4.58% 1D, market cap $98.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PMVP ranks #426 in composite RQD confidence.
How does PMVP compare to ORGO and VTVT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMVP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $99.5M). Among the 5-stock peer group, PMVP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PMVP?
Per PMVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699382), PMV Pharmaceuticals Inc. generated $241.4M in revenue (+0.9% YoY), -$77.7M in net income, and -$73.6M in free cash flow against $116.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PMVP trading relative to its 50-day, 200-day, and 52-week technical levels?
PMVP last traded at $1.37 (+4.58% on volume of 440,428 shares), positioning the stock -0.72% below its 50-day simple moving average ($1.38) and +5.38% above its 200-day simple moving average ($1.30). Across its 52-week range of $1.02 to $1.91, PMVP sits at the 39.3% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ SEC XBRL & RQD VERIFIED
PMVP — PMV Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
PMV Pharmaceuticals Inc. (PMVP) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.37 (+4.58% 1D, market capitalization $98.9M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (14/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
PMV Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. — for products, customers, and revenue model; the financials report revenue of — in each reported period, so the current income-generation model cannot be characterized from the source data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PMV Pharmaceuticals Inc. (PMVP) reported $241.4M in annual revenue (up from $239.3M in FY2024, +0.9% YoY) and -$77.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($224.4M revenue, -$69.0M net income) through FY2025, PMVP scaled operating cash flow to -$73.6M and free cash flow to -$73.6M, backed by $116.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $1.02 – $1.91 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The 2nd-order bottleneck a prospective investor should monitor is therefore not identifiable from the supplied sources; the company's own cash balance trajectory ($40.9M to $38.0M) against sustained negative free cash flow is the only documented pressure point.
- Key Question #1: Can PMVP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $241.4M and free cash flow of -$73.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is PMVP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PMVP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for PMV Pharmaceuticals Inc. (PMVP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know Yahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity Seeking Alpha report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates kalkine.ca report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
PMV Pharmaceuticals, Inc. Estimates – NASDAQ:PMVP TradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 2d ago
PMV Pharma appoints Matt Eckler to board of directors By Investing.com Investing.com India report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 2d ago
PMV Pharmaceuticals stock moves above 200-day average as analysts stay mixed ad-hoc-news.de report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
Should You Buy PTC Inc. (PTC) After Golden Cross? Yahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
PMVP Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PMVP Bull vs. Bear Conversation Board — What's Your Call at $1.37?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMVP 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.66 (+26.7%)
📌 Pinned Debate The stock has risen 19% over three months and moved above its 200-day average, indicating recent price momentum despite negative fundam
The stock has risen 19% over three months and moved above its 200-day average, indicating recent price momentum despite negative fundamentals.. When you look under the hood at PMVP, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $1.91. My 12M target is $1.66.
CapAlloc_Nerd 🐂 BULL
@DeepValue_CFA Agree on the RQD 42/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.31 and keeping dry powder in case we test $1.22.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $0.98 (-25.2%)
Spot @ $1.31 With $0.0M revenue, -35% ROIC, 0% FCF yield, and negative free cash flow in every reported period, the business shows no current cash-g
Careful chasing PMVP at $1.31. With $0.0M revenue, -35% ROIC, 0% FCF yield, and negative free cash flow in every reported period, the business shows no current cash-generating earnings base.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.98 on multiple compression.